GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Logo poskytovatele

Varování

Publikace nespadá pod Pedagogickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Název česky GLP-1 agonisté: superiorní pro mozek a tělo u pacientů léčených antipsychotiky?
Autoři

HORSKÁ Kateřina RUDÁ Jana SKREDE Silje

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj TRENDS IN ENDOCRINOLOGY AND METABOLISM
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub
Doi http://dx.doi.org/10.1016/j.tem.2022.06.005
Klíčová slova antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia
Popis Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.